Initial Clinical Experience With Novel Directional Low-Dose Rate Brachytherapy for Retroperitoneal Sarcoma.

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Retroperitoneal sarcoma (RPS) presents treatment challenges, particularly for recurrent or locally advanced cases.
• Novel brachytherapy techniques are needed for targeted dose escalation after surgical resection.
• Shielding adjacent tissues while delivering radiation to the tumor bed is crucial.

Purpose of the Study:

• To evaluate the initial clinical experience with a novel Palladium-103 low-dose rate (LDR) brachytherapy device for RPS.
• To assess the safety and efficacy of dose escalation to the tumor bed in patients with RPS.
• To determine the feasibility of using this device to treat high-risk margins in RPS.

Main Methods:

• A multicenter study involving six patients with RPS undergoing implantation of a Palladium-103 LDR brachytherapy device.
• Doses administered ranged from 20-60 Gy (LDR), with corresponding biologically effective doses (BED) and equivalent doses (EQD).
• Patients included those with recurrent RPS, positive margin concerns, or prior radiotherapy.

Main Results:

• The device was successfully implanted in six patients across four institutions, conforming well to the treatment area.
• Median follow-up was 16 months, with radiation delivered precisely to the at-risk margin.
• No local recurrences, device migration, or radiation-related toxicities were observed in the treated patients.

Conclusions:

• The novel LDR directional brachytherapy device effectively delivered targeted dose escalation for RPS high-risk margins.
• The observed lack of radiation-related toxicity confirms the safety profile of this innovative treatment approach.
• This technology shows promise for improving outcomes in the management of retroperitoneal sarcoma.